Unique ID issued by UMIN | UMIN000018581 |
---|---|
Receipt number | R000020409 |
Scientific Title | The importance of home blood pressure in patients with diabetes. |
Date of disclosure of the study information | 2015/08/07 |
Last modified on | 2016/08/07 10:00:01 |
The importance of home blood pressure in patients with diabetes.
home blood pressure in patients with diabetes.
The importance of home blood pressure in patients with diabetes.
home blood pressure in patients with diabetes.
Japan |
diabetes mellitus
Medicine in general | Cardiology | Endocrinology and Metabolism |
Others
NO
The aim of the present study is to provide an innovative thrapeutic means for the prevention and treatment of microvascular and macrovascular complications in patients with diabetes mellitus.
Others
The aim of the present study is to compare the effects on home blood pressure and home blood pressure variability of combination therapy of olmesartan combined with azelnidipine or trichlormethiazide in patients with type 2 diabetes mellitus using home blood pressure telemonitoring system.
home blood pressure and home blood pressure variability at least 28 days after randomization or switching drugs.
Interventional
Cross-over
Randomized
Open -no one is blinded
Active
2
Treatment
Medicine |
olmesartan 20mg and azelnidipine 16mg, olmesartan 20mg and trichlormethiazide 1mg for more than 6 weeks each
We used HBP data at least 28 days after randomization or switching drugs.
olmesartan 20mg and trichlormethiazide 1mg, olmesartan 20mg and azelnidipine 16mg for more than 6 weeks each
We used HBP data at least 28 days after randomization or switching drugs.
40 | years-old | <= |
80 | years-old | > |
Male and Female
Inclusion criteria were as follows: 40-80 years, type 2 diabetes mellitus, hypertension with the use of RAS inhibitors, RAS inhibitors and CCBs, or RAS inhibitors and diuretics.
Exclusion criteria were as follows: secondary hypertension or malignant hypertension, history of cerebrovascular accident, myocardial infarction or hospitalization for angina pectoris within 6 months before evaluation for study entry, advanced liver or renal dysfunction (serum creatinine equal to or more than 2.0mg/dl or current treatment by dialysis), atrial fibrillation or severe arrhythmia, prescribed 3 and over antihypertensive drugs, prescribed other class of antihypertensive drugs than study drugs (that is, RAS inhibitors, CCBs or diuretics), history of side effects from study drugs, life-threatening condition like malignant tumor or not suited to be a study patients as judged by a physician in charge.
50
1st name | |
Middle name | |
Last name | Michiaki Fukui |
Kyoto Prefectural University of Medicine, Graduate School of Medical Science
Department of Endocrinology and Metabolism
465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
075-251-5505
michiaki@koto.kpu-m.ac.jp
1st name | |
Middle name | |
Last name | Emi Ushigome |
Kyoto Prefectural University of Medicine, Graduate School of Medical Science
Department of Endocrinology and Metabolism
465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
075-251-5505
emis@koto.kpu-m.ac.jp
Kyoto Prefectural University of Medicine, Graduate School of Medical Science
Emi Ushigome received grant support from Japanese Study Group for Physiology and Management of Blood Pressure and Astellas Foundation for Research on Metabolic Disorders.
Other
NO
2015 | Year | 08 | Month | 07 | Day |
Unpublished
Completed
2014 | Year | 04 | Month | 01 | Day |
2014 | Year | 04 | Month | 01 | Day |
2015 | Year | 08 | Month | 07 | Day |
2016 | Year | 08 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020409
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |